Sure, as is the case with other long-shot vaccine plays, the company has other candidates in its pipeline. Yet, while there may be potential with its OCU400 "gene therapy product" for retinal diseases, that's far from enough to support the stock at its current valuation. Right now, OCGN has a market capitalization of $1.88 billion. Even with the $23 million in proceeds from its recent direct offering, Ocugen still doesn't have the balance sheet to support that lofty number, either.